Cardiovascular Safety of Nilotinib in Alzheimer Disease

Sean Tan¹, Diva Baggio², Jake Shortt^{2

3}, Brian Ko^{1

4}

Affiliations

¹ MonashHeart, Monash Health, Clayton, Victoria, Australia.
² Monash Haematology, Monash Health, Clayton, Victoria, Australia.
³ School of Clinical Sciences at Monash Health, Faculty of Medicine Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
⁴ Monash Cardiovascular Research Centre, Monash University, Clayton, Victoria, Australia.

Comment

Sean Tan et al. Ann Neurol. 2021 Jan.

. 2021 Jan;89(1):196.

doi: 10.1002/ana.25947. Epub 2020 Nov 7.

Sean Tan¹, Diva Baggio², Jake Shortt^{2

3}, Brian Ko^{1

4}

¹ MonashHeart, Monash Health, Clayton, Victoria, Australia.
² Monash Haematology, Monash Health, Clayton, Victoria, Australia.
³ School of Clinical Sciences at Monash Health, Faculty of Medicine Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
⁴ Monash Cardiovascular Research Centre, Monash University, Clayton, Victoria, Australia.

No abstract available

Comment in

Reply to "Cardiovascular Safety of Nilotinib in Alzheimer's Disease".
Moussa C. Moussa C. Ann Neurol. 2021 Jan;89(1):196-197. doi: 10.1002/ana.25946. Epub 2020 Nov 6. Ann Neurol. 2021. PMID: 33103265 No abstract available.

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.
Turner RS, Hebron ML, Lawler A, Mundel EE, Yusuf N, Starr JN, Anjum M, Pagan F, Torres-Yaghi Y, Shi W, Mulki S, Ferrante D, Matar S, Liu X, Esposito G, Berkowitz F, Jiang X, Ahn J, Moussa C. Turner RS, et al. Ann Neurol. 2020 Jul;88(1):183-194. doi: 10.1002/ana.25775. Epub 2020 May 28. Ann Neurol. 2020. PMID: 32468646 Free PMC article.